Royalty Pharma (RPRX) Q3 2026 earnings review
Royalty Pharma raises its cash outlook, but pelacarsen fails
Royalty Pharma, a buyer of rights to pharmaceutical sales, raised its full-year cash outlook as new medicines offset generic erosion, but a late-stage trial failure hit its pipeline. Portfolio receipts grew 9% to $890 million on fast uptake of cancer and rare-disease drugs, prompting chief executive Pablo Legorreta to lift the full-year target by $75 million at the middle of the range. By our math, the new plan points to about 7% growth in the fourth quarter.
| Portfolio receipts | $890M +9% from a year ago |
|---|---|
| Royalty receipts | $883M +9% (+5.3% ex-Imdelltra & Amvuttra by our math) |
| Full-year portfolio receipts outlook | Raised $75M middle of the range: 8.3% growth |
| Pelacarsen trial write-down | $150M GAAP net income fell 49% to $145M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because commercial momentum and pipeline setbacks moved in opposite directions. Newly launched drugs and five US regulatory approvals strengthened current cash collections, yet Novartis's pelacarsen failed its Phase 3 heart trial, forcing a $150 million write-down and testing a major drug class in the long-term pipeline. One caution: excluding late-2025 acquisitions, royalty receipts grew about 5% by our math, and net royalty assets on the balance sheet stayed flat for a second quarter.
The question now is whether recent drug approvals can grow the royalty asset base faster than older drugs roll off. Either new launches like Rasonque and Imdelltra lift underlying growth on their own, or the firm must spend over $2 billion a year on deals just to stand still. Fourth-quarter capital deployment and the initial 2027 outlook will decide.
🐂 Bull Case
New Drug Launches Drive Third Outlook Raise
“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” chief executive Pablo Legorreta said. The buyer of pharmaceutical royalties tracks its top line through portfolio receipts, which combine regular sales royalties with one-off milestone payments. Management lifted its full-year target for a third time this year, and each raise has grown larger.
- Recent drug launches (Voranigo for brain cancer, Imdelltra for lung cancer, Amvuttra for nerve and heart disease): $84 million in Q3, up from $71.1 million in Q2
- Tremfya (immunology): $80 million, up 61% from a year ago
- Full-year portfolio receipts outlook: raised by $75 million at the middle of the range, following raises of $37.5 million in Q1 and $62.5 million in Q2
This matters because the newest medicines now account for 9.5% of total royalty receipts, by our math, and are growing fast enough to absorb generic competition on older drugs. What to watch: fourth-quarter receipts from Voranigo, Imdelltra and Amvuttra. Another sequential step-up above $84 million would confirm that recently launched drugs can carry growth into 2027.
FDA Approvals De-Risk the Future Pipeline
Royalty Pharma funds clinical trials and buys royalty rights before drugs reach the market, so regulatory approvals turn its pipeline bets into cash streams. During the quarter, drugmakers won US Food and Drug Administration approvals for five medicines in the portfolio, while two more passed late-stage trials.
- Rasonque (pancreatic cancer): won US approval in August and a positive European opinion in October
- Weltruza (schizophrenia), Ziihera (stomach cancer), Mimrylo (blood disorder) and Jideytro (lung cancer): all received US approval
- Imdelltra (first-line lung cancer maintenance) and deucrictibant (hereditary swelling): both met primary goals in Phase 3 trials
These approvals shift multiple therapies from development into commercial sales, which expands the company's roster of marketed products above 35. What to watch: initial commercial royalty receipts from Rasonque and Ziihera in early 2027. Meaningful early collections would show these new approvals can replace maturing blockbusters.
Positives this quarter didn't test
Three standing positives in the business case received no new evidence in the third-quarter release.
- R&D co-funding with large drugmakers: Legorreta called it “an important new opportunity for our business”, but total deals stayed at the $1 billion already signed in the first quarter; the next new co-funding deal will test demand.
- Buying multiple royalties in a single disease area: the company bought Zoryve (skin disease) and Mimrylo (blood disorder) for $100 million each rather than adding to existing categories; future deal announcements will show if the multi-asset approach continues.
- Return on invested capital and equity: not included in the earnings release; the quarterly slide deck or filing will update those return figures.
🐻 Bear Case
Pelacarsen Trial Failure Forces $150M Write-Down
Royalty Pharma holds royalty rights on 16 development-stage drug candidates to drive its long-term growth, although clinical trial failures can wipe out those investments. One of its biggest pipeline bets was pelacarsen, a Novartis heart drug designed to lower a genetic cholesterol marker called Lp(a).
In September, Novartis reported that the Phase 3 trial of pelacarsen “did not meet its primary endpoint of reducing the risk of cardiovascular events in the overall study population compared to placebo”. In addition, Syndax halted idiopathic pulmonary fibrosis trials for Niktimvo after a Phase 2 miss. Royalty Pharma recorded a $150 million non-cash impairment charge on pelacarsen, equal to 21.7% of GAAP revenue, which pushed GAAP net income attributable to shareholders down 49% to $145 million (or $295 million excluding the write-down, by our math).
The pelacarsen miss matters beyond the $150 million write-down because it was the first cardiovascular outcomes readout for the Lp(a) drug class, where the firm has concentrated its pipeline exposure. What to watch: any management disclosure on remaining Lp(a) carrying values in the quarterly filing. A further write-down or timetable delay on related heart candidates would reduce the company's long-term pipeline potential.
Acquisitions Carry Growth While Asset Base Stalls
Legorreta highlighted 9% growth in royalty receipts to $883 million, but older medicines continue to shrink and recent deals did much of the heavy lifting. Every drug patent eventually expires, so the firm must continually buy new royalties to offset fading ones.
- Royalty receipts excluding Imdelltra and Amvuttra (acquired in late 2025): up 5.3% from a year ago by our math, and that still “included the benefit of the additional royalties acquired in December 2025” on Evrysdi (+38% to $71 million)
- Aging drugs: Promacta fell 75% to $9 million and Imbruvica dropped 24% to $31 million, while Trelegy slipped 6% to $89 million
- Net financial royalty assets on the balance sheet: $17,079 million, down $3 million from June and down $243 million since March
- Revolution Medicines funding: the partner “elected not to exercise its option for the third royalty funding tranche” of up to $250 million
Because drug collections are matching or exceeding new investments, the capitalised pool of future royalties on the balance sheet has stopped growing for two straight quarters. What to watch: full-year capital deployment at the fourth-quarter report. Full-year spending well below $2 billion would mean portfolio decay is outpacing replacement.
Risks this quarter didn't answer
Three standing risks were not addressed in the third-quarter earnings release.
- Vertex cystic fibrosis dispute and concentration: the franchise generated $225 million (+1% from a year ago), or 25% of portfolio receipts, while Vertex pays a 4% rate on Alyftrek instead of the claimed 8%; the legal proceedings note in the 10-Q or mid-2027 arbitration will update it.
- US and international drug-pricing rules: no sizing of Medicare negotiation or reference-pricing exposure; future management commentary or 2027 guidance will show any impact.
- Executive equity awards and dilution: employee performance award cash payments were $3 million in Q3 ($18 million year-to-date) and share-based compensation was $105 million; the 10-Q footnote will detail unvested Class E shares.
💲 Other KPIs
Cash spent on royalty deals and trial funding fell 64% from $1,013 million a year ago, when the company bought Imdelltra. Spending has stayed below $400 million for two quarters after $528 million in the first quarter. Nine-month deployment reached $1,239 million, led in the third quarter by upfront payments for cliramitug, Zoryve and Mimrylo.
Portfolio cash flow — portfolio receipts minus operating costs and net interest paid — rose 2% from $657 million a year ago, slowing from 15% growth in the second quarter. Semi-annual bond interest payments of $167 million net (up from $123 million a year ago) held back cash flow in the third quarter.
Principal debt fell by $400 million from $9.2 billion at the end of June because Royalty Pharma paid off its $380 million term loan at maturity in July. Cash and equivalents finished the quarter at $514 million, down from $812 million in June after the debt payoff and $135 million in dividends.
Diluted Class A shares were unchanged from the first and second quarters and down 0.5% from 560 million a year ago. The firm spent $87 million to buy back 1.5 million shares in the third quarter, up from $45 million in the second quarter but below $152 million a year ago.
🔮 Guidance
Raised. The middle of the range moved up $75 million to $3,525 million, or 8.3% growth for the year (with royalty receipts up 10% to 11%). By our math, that leaves $937 million for the fourth quarter, or 7.2% growth from a year ago vs 9.3% in the third quarter. It is the third raise this year, and each was larger than the last: +$37.5M, +$62.5M, +$75M.
Tightened lower. Management trimmed the top end of the cost range by 0.5 percentage points, down from 8.9% in 2025 after buying out its external manager in May 2025. Costs ran at 5.6% in the third quarter and $123 million for the first nine months; by our math, the 5.75% full-year middle of the range implies 8.5% in the fourth quarter.
Unchanged. The full-year plan still calls for $350 million to $360 million of gross interest payments. Because the company has already paid $352 million across the first nine months (including $173 million in the third quarter), management expects fourth-quarter interest payments to be a negligible amount, matching its bond payment schedule.
❓ Key Questions
What drove the $88 million provision benefit this quarter?
After recording a $268 million provision expense in the second quarter (driven by Adstiladrin and cystic fibrosis), the company booked an $88 million benefit in the third quarter. The release does not name which drug forecasts improved.
How much Lp(a) exposure remains after pelacarsen failed?
Royalty Pharma wrote off $150 million on Novartis's pelacarsen after its Phase 3 cardiovascular trial failed. Investors need to know the remaining carrying value of pelacarsen and whether the failure changes expectations for other Lp(a) heart drugs.
Why did Revolution Medicines decline the $250M royalty tranche?
Revolution Medicines drew its $250 million loan tranche after Rasonque won FDA approval, but chose not to take an optional $250 million royalty tranche. That reduces the amount of high-returning royalty capital Royalty Pharma deploys into one of its marquee deals.
What was royalty growth excluding all recent acquisitions?
Stripping out Imdelltra and Amvuttra lowers third-quarter royalty receipts growth from 9% to 5.3% by our math, and that figure still includes the extra Evrysdi stake bought in December 2025. Management does not disclose a clean underlying growth rate.